Premium
Liver Enzyme Induction and Serum Lipid Levels After Replacement of Carbamazepine with Oxcarbazepine
Author(s) -
Isojärvi Jouko I. T.,
Pakarinen Arto J.,
Rautio Arja,
Pelkonen Olavi,
Myllylä Vilho V.
Publication year - 1994
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1994.tb01792.x
Subject(s) - carbamazepine , oxcarbazepine , liver enzyme , endocrinology , medicine , phenytoin , lipid metabolism , enzyme inducer , epilepsy , liver function , anticonvulsant , pharmacology , enzyme , chemistry , biochemistry , psychiatry
Summary: We evaluated liver P450 enzyme system induction and serum lipid levels in a prospective follow–up study in 12 male patients with epilepsy after replacing carbamazepine (CBZ) medication with oxcarbazepine (OCBZ). Antipyrine 1 1/2 increased and antipyrine CL decreased 2 months after the medication was changed, reflecting normalization of liver P450 enzyme system function. Furthermore, serum total cholesterol levels decreased, but serum concentrations of high‐density lipoprotein (HDL)‐cholesterol and triglycerides (TG) were unchanged. OCBZ may be the preferable antiepileptic drug (AED) with regard to the effects of the medication on lipid metabolism.